|
ask your doctor about the trastuzumab-dm1 trial...
in july genentech is starting a new trial with tras-dm1 going head to head with herceptin/taxotere. the last reported news about tras-dm1 from asco 2008 is stunning to say the least.. about 80% of the patients so far have stable disease or at least partial response... and MPB just stated she is NED and has the paper to prove it... good luck...
run to live
St. Barnabas Health Care Sys Recruiting Livingston, New Jersey, United States, 07039 Contact: Ilda Boholli 973-322-2470 iboholli@sbhcs.com United States, New YorkEastchester Center/Cancer Care Recruiting Bronx, New York, United States, 10469 Contact: Karen Hoffman 718-732-4029 karen@eastchestercenter.com New York Oncology Hematology Recruiting Albany, New York, United States, 12206 Contact: Mary Beth Biette 518-489-0528 mary.biette@usoncology.com
Dr S, Modi at Sloan Kettering is also running alternate weekly dosing regimens
|